Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS212 + JS111
- Development stage
- Phase 2
- Lead developer
- Junshi Biosciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
JS212 + JS111 is a combination therapy being developed by Shanghai Junshi Bioscience for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. JS212 is a recombinant humanized bispecific antibody-drug conjugate (ADC) targeting both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). JS111 (also known as AP-L1898) is a small molecule inhibitor targeting EGFR exon 20 insertion mutations. The combination is designed to overcome resistance in patients who have progressed after prior EGFR tyrosine kinase inhibitor (TKI) therapy by simultaneously targeting multiple pathways and utilizing the cytotoxic payload of the ADC to induce tumor cell death.
- Other names
- JS212 + AP-L1898
02
Targets
EGFR (Epidermal growth factor receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on JS212 + JS111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS212 + JS111.